These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 22231583

  • 1. Use of PET/CT to evaluate response to therapy in lymphoma.
    Zanoni L, Cerci JJ, Fanti S.
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):633-47. PubMed ID: 22231583
    [Abstract] [Full Text] [Related]

  • 2. PET/CT for therapy response assessment in lymphoma.
    Hutchings M, Barrington SF.
    J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [Abstract] [Full Text] [Related]

  • 3. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go.
    Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czernin J.
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):620-32. PubMed ID: 22231582
    [Abstract] [Full Text] [Related]

  • 4. Imaging of therapy response in oncology.
    Chiti A, Oyen WJ.
    Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):587-8. PubMed ID: 22231579
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H.
    Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Role of functional imaging in the management of lymphoma.
    Cheson BD.
    J Clin Oncol; 2011 May 10; 29(14):1844-54. PubMed ID: 21482982
    [Abstract] [Full Text] [Related]

  • 10. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
    Tsujikawa T, Otsuka H, Morita N, Saegusa H, Kobayashi M, Okazawa H, Nishitani H.
    Ann Nucl Med; 2008 Jan 10; 22(1):23-30. PubMed ID: 18250984
    [Abstract] [Full Text] [Related]

  • 11. Staging and response assessment in lymphomas: the new Lugano classification.
    Cheson BD.
    Chin Clin Oncol; 2015 Mar 10; 4(1):5. PubMed ID: 25841712
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. MRI and PET in monitoring response in lymphoma.
    Rahmouni A, Luciani A, Itti E.
    Cancer Imaging; 2005 Nov 23; 5 Spec No A(Spec No A):S106-12. PubMed ID: 16361125
    [Abstract] [Full Text] [Related]

  • 15. Quantitative CT analysis for assessing response in lymphoma (Cheson's criteria).
    Rahmouni A, Luciani A, Itti E.
    Cancer Imaging; 2005 Nov 23; 5 Spec No A(Spec No A):S102-6. PubMed ID: 16361124
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Revolutionary impact of PET and PET-CT on the day-to-day practice of medicine and its great potential for improving future health care.
    Basu S, Alavi A.
    Nucl Med Rev Cent East Eur; 2009 Nov 23; 12(1):1-13. PubMed ID: 19554516
    [Abstract] [Full Text] [Related]

  • 18. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
    Krause BJ, Herrmann K, Wieder H, zum Büschenfelde CM.
    J Nucl Med; 2009 May 23; 50 Suppl 1():89S-96S. PubMed ID: 19380406
    [Abstract] [Full Text] [Related]

  • 19. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics.
    Chen Z, Li X, Li F, Ouyang Q, Yu T.
    Eur J Radiol; 2010 Sep 23; 75(3):329-35. PubMed ID: 20576385
    [Abstract] [Full Text] [Related]

  • 20. Magnetic resonance imaging of malignant lymphoma.
    Vermoolen MA, Kersten MJ, Fijnheer R, van Leeuwen MS, Kwee TC, Nievelstein RA.
    Expert Rev Hematol; 2011 Apr 23; 4(2):161-71. PubMed ID: 21495926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.